#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

### FORM 8-K

### CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 2, 2015

Commission File Number: 000-50768

# **ACADIA Pharmaceuticals Inc.**

(Exact name of registrant as specified in its charter.)

<u>Delaware</u> (State or other jurisdiction of incorporation or organization) <u>061376651</u> (IRS Employer Identification No.)

<u>3611 Valley Centre Drive, Suite 300, San Diego, California 92130</u> (Address of principal executive offices)

<u>858-558-2871</u>

(Registrant's Telephone number)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On November 2, 2015, Lester Kaplan, Ph.D. notified us of his resignation as a member of our Board of Directors and as a member of committees of our Board, effective immediately. On November 4, 2015, Roger Mills, M.D. notified us of his resignation as Executive Vice President, Development and Chief Medical Officer, effective immediately.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## ACADIA Pharmaceuticals Inc.

Date: November 6, 2015

By: /s/ Glenn F. Baity

Name: Glenn F. Baity Title: Executive Vice President, General Counsel & Secretary